ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
14/03/2025
Voltar para busca
Dado oficial do USPTO
OCLAIZ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
15/03/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
27/04/2022
Data de registro
23/01/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/01/2024
Última transação
15/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
16
Localização do titular
SE
Examinador
BULLOFF, TOBY
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Camurus AB
Representantes
Karen Kreider Gaunt Dinsmore & Shohl LLP
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone
Classe 10
Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/12/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/12/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
13/05/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/04/2024
FIMP
FINAL DISPOSITION PROCESSED
24/04/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/01/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
23/01/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
13/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/12/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/12/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2023
PUBO
PUBLISHED FOR OPPOSITION
07/11/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/10/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/10/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/10/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/10/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/10/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/07/2023
RFNT
REFUSAL PROCESSED BY IB
25/04/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2023
RFRR
REFUSAL PROCESSED BY MPU
05/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
17/02/2023
CNRT
NON-FINAL ACTION WRITTEN
16/02/2023
DOCK
ASSIGNED TO EXAMINER
15/02/2023
MAFR
APPLICATION FILING RECEIPT MAILED
26/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/07/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/07/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OCLAIZ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.